39 results about "Chronic infectious disease" patented technology

The invention discloses micro ribonucleic acids (microRNA, miRNA) carried by cell microparticles (Microparticle, MP), a method for preparing the same, and application thereof in the technical field of biotechnological pharmacy. The invention provides a combination of the micro ribonucleic acids for evaluating the physiological and / or pathological states of a participant, and the combination contains all the micro ribonucleic acids which exist stably in serum / plasma particles of the participant and are detectable. At the same time, the invention provides an experimental method for preparing the cell microparticles containing specific micro ribonucleic acids and using the cell microparticles to perform gene-level regulation and control as well as modification on other cells and tissues. The combination and the method can be used for detecting and treating various diseases, including the aspects of the diagnosis and the differential diagnosis of various tumors, various acute and chronic infectious diseases and other acute and chronic diseases, the prediction and the curative effect evaluation of the occurrences of disease complications and the recurrences of malignant diseases, as well as the active ingredient screening, the efficacy evaluation and the judicial authentication of drugs, the detection of prohibited drugs and the like; besides, the combination and the method have the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient available material, easy storage of samples and the like.

The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.

The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective / preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.

The invention discloses an anti-PD-L1 antibody as well as application, a preparation method, a kit and a drug, and relates to the technical fields of biological detection and treatment. The anti-PD-L1 antibody provided by the invention contains a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 5, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 6. The anti-PD-L1 antibody can be combined with PD-L1 recombinant proteins and inflammation tissue cells or tumor tissue cells expressing PD-L1 molecules via specific recognition, so that the anti-PD-L1 antibody has a relatively high specificity and avidity, can be used for immunoblotting, enzyme-linked immuno sorbent assay, immunohistochemistry and flow cytometry and can also be used for treating diseases of tumors, immunological diseases, chronic infectious diseases and the like.

This invention provides a combination of microRNAs for evaluating the physiological and / or pathological condition of a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum / plasma of a subject; and a method for evaluating the physiological and / or pathological condition of a subject, wherein the method includes determining all detectable microRNAs stably existing in the serum / plasma of a subject; and a kit for evaluating the physiological and / or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum / plasma of a subject; and a biochip for evaluating the physiological and / or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum / plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors; various acute / chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute / chronic infectious diseases caused by various pathogenic microorganisms; other acute / chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system, prediction of complications occurrence and malignant diseases relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy as well as forensic authentication and prohibited drug inspection and the like, possessing a number of advantages such as extensive detection spectrum, high sensitivity, low cost, convenience for sampling, ease for sample preservation, etc. The said method can be widely used in work related to general survey of diseases and so on, improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, significantly increasing the clinical detection rate of diseases, all of which make it become an effective means for diagnosing diseases in an early phase.

A method for treating an individual suffering from a chronic infectious disease and who has cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.

The invention provides recombinant porcine interleukin (IL) 4-Fc fusion protein, a coding gene and an expression, purification and inclusion body renaturation method thereof, which belong to the field of the biological genetic engineering. Porcine IL4 can be used for treating porcine chronic infectious diseases and parasitic diseases and can be further popularized and applied to preventing and treating diseases such as porcine anaphylactic reaction and the like which are related to immunity. However, the porcine IL4 has the defects of high clearing speed in plasma and high industrialization cost. The invention provides long-acting recombinant porcine IL4-Fc fusion protein by adopting an escherichia coli prokaryotic expression system, wherein the porcine IL4 part includes the whole sequence of a porcine IL4 extracellular region, the Fc segment part includes a hinge region of antibodies, a CH2 region and a CH3 region, and the porcine IL4 part and the Fc segment part are directly fused. According to the recombinant porcine IL4-Fc fusion protein provided by the invention, the biological activity of the IL4 is improved, the half-life period of the IL4 is greatly prolonged, and the guarantee is provided for the low-cost mass expression and the industrialization of the expression.

In alternative embodiments, provided are novel applications of bacteria which originate from the phylum of Actinobacteria and sub-order Corynebacterineae, family Dietziaceae, including genus Dietzia and other genera. Such bacilli can profoundly interfere with bacteria generally belonging to this and other phyla, and can be useful in treating chronic infections. Hence, such organisms can ameliorateor cure clinical infections caused by pathogens from the phylum such as Mycobacteriaceae and Mycobacterium such as M. tuberculosis and Mycobacterium avium subspecies paratuberculosis (MAP).

A freeze-dried powder injection of VC for preventing and treating scurvy, acute and chronic infectious diseases, purpura, Keshan disease, etc is prepared from VC, sodium hydrogen sulfate, and disodium versenate through ultrasonic treating, adding CO2 saturated water for injection in dark condition and N2 atmosphere, regulating pH value and temp, etc.

The invention relates in general to polypeptides having a primary sequence that is highly homologous with the sequence of human interleukin-2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the invention have an immunomodulating effect on the immune system, which is selective / preferential in relation to regulatory T cells. The invention also relates to specific polypeptides of which the amino acid sequence is disclosed in the present invention. The invention further relates to pharmaceutical compositions containing the disclosed polypeptides as an active principle. Finally, the invention relates to the therapeutic use of said polypeptides and pharmaceutical compositions, given the immune-system-modulating effect thereof on pathologies such as cancer and chronic infectious diseases.

The present invention relates to antagonistic antigen binding proteins, a nucleic acid encoding the antagonistic binding protein, a recombinant expression vector comprising the nucleic acid molecule,a host cell comprising the vector, a method of making the antagonistic antigen binding protein, an antagonistic binding protein produced by the method and a pharmaceutical composition comprising the antagonistic binding protein, the nucleic acid or the vector. The present invention further relates to a kit comprising the pharmaceutical composition and use of the antagonistic binding protein in thetreatment of cancer and / or chronic infectious diseases.

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

In alternative embodiments, provided are novel applications of bacteria which originate from the phylum of Actinobacteria and sub-order Corynebacterineae, family Dietziaceae, including genus Dietzia and other genera. Such bacilli can profoundly interfere with bacteria generally belonging to this and other phyla, and can be useful in treating chronic infections. Hence, such organisms can ameliorate or cure clinical infections caused by pathogens from this phylum such as Mycobacteriaceae and Mycobacterium such as M. tuberculosis and Mycobacterium avium sub species paratuberculosis (MAP).

The invention discloses a traditional Chinese medicine preparation for treating children pulmonary tuberculosis. The pulmonary tuberculosis is a chronic infectious disease and belongs to the category of consumption in traditional Chinese medicine; the pathogenesis key points comprise lung yin deficiency, spleen and stomach deficiency, qi and blood loss and yin-yang deficiency. According to the invention, based on the principles of strengthening the body resistance and eliminating evil, traditional Chinese medicines, namely African malcolmia seed, pearl grass, Japanese platanthera herb, corniculate cayratia root, storax, calamus, curious kadsura fruit, asiatic bilberry, kohlrabi, cynanchum otophyllum, Chinese velvetbean seed or leaf and auriculate swallowwort root which have the effects of nourishing yin, clearing heat, relieving cough, reducing sputum, tonifying spleen and benefiting kidney are decocted into a decoction by using water; and proved by clinic tests, the total effective rate is up to 98.0% and the curative effect is remarkable.

The invention discloses an anti-PD-L1 antibody as well as application, a preparation method, a kit and a drug, and relates to the technical fields of biological detection and treatment. The anti-PD-L1 antibody provided by the invention contains a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 5, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 6. The anti-PD-L1 antibody can be combined with PD-L1 recombinant proteins and inflammation tissue cells or tumor tissue cells expressing PD-L1 molecules via specific recognition, so that the anti-PD-L1 antibody has a relatively high specificity and avidity, can be used for immunoblotting, enzyme-linked immuno sorbent assay, immunohistochemistry and flow cytometry and can also be used for treating diseases of tumors, immunological diseases, chronic infectious diseases and the like.

The invention relates to Xenopsylla cheopis polypeptide and a gene and application thereof, in particular to application of Xenopsylla cheopis polypeptide FS48 in preparation of medicine for treating pain, cancer, inflammatory diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases and chronic infectious diseases related to Kv1.1. The amino acid sequence of the Xenopsylla cheopis polypeptide FS48 is shown as SEQ ID NO:1. The polypeptide is prepared by conducting prokaryotic expression of Xenopsylla cheopis polypeptide FS48 and then conducting three-step column chromatography separation and purification. The Xenopsylla cheopis polypeptide FS48 has the pain relief, anti-inflammation, immunoregulation and anti-tumor effects by inhibiting Kv1.1 and Kv4.1 and has no cytotoxicity.